Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지

A Case Report and Literature Review : Treatment of Nasopharyngeal Cancer(NPC) Patient with AOSD(Adult Onset Still's Disease)

성인형 스틸씨 병에서 병발된 비인두암의 치료 및 문헌 고찰

  • Kim, Jun Young (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Kim, Jin Dong (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Kyung Bin (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Won Jae (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Na, Gun Wung (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Park, Wonil (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Park, Gi Cheol (Department of Otolaryngology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Kim, Tae Gyu (Department of Radiation Oncology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Ji, Jun Ho (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine)
  • Received : 2013.12.31
  • Accepted : 2014.02.20
  • Published : 2014.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

비인두암에서 시행되는 방사선 치료 이후에 구강건조증과 피부 변화는 흔하게 볼 수 있는 합병증 중 하나이다. 비인두암의 좋은 예후를 고려할 때, 그러한 치료와 관련된 독성들은 상대적으로 오랫동안 문제를 야기하며 삶의 질 저하를 불러온다. 특히 류마티스 관절염, 루푸스와 같은 결합조직 질환을 가진 환자들에게서 방사선 치료를 시행하였을 때, 빈번하게 심각한 독성이 관찰된다. 본 증례는 성인형 스틸씨 병에서 병발된 비인두암의 치료로 항암방사선 동시치료를 실시한 결과, 비교적 경미한 구강 건조, 점막염, 불면증 등의 합병증이 관찰되었으나, 완전 관해가 획득되었다. 이에 저자들은 과거에 보고된 적 없는 성인형 스틸씨 병에 병발한 비인두암의 치료 경험을 다른 결합조직질환들에서 방사선 치료의 문헌들과 함께 보고하는 바이다.

Keywords

References

  1. Afqir S, Ismaili N, Errihani H. Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: Current status. Journal of Cancer Research and Therapeutics. 2009;5:3-7. https://doi.org/10.4103/0973-1482.48763
  2. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal Carcinoma. 2002; 13:1007-1015.
  3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013;63:11-30. https://doi.org/10.3322/caac.21166
  4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011; 61:69-90. https://doi.org/10.3322/caac.20107
  5. Kim TH, Ko YH, Lee MA, Kim BS, Chung SR, Yoo IeR, et al. Treatment outcome of cisplatin-based concurrent chemoradiotherapy in the patients with locally advanced nasopharyngeal cancer. Cancer research and treatment: Official Journal of Korean Cancer Association. 2008;40:62-70. https://doi.org/10.4143/crt.2008.40.2.62
  6. Chu ST, Wu PH, Hou YY, Chang KP, Chi CC, Lee CC. Primary tumor volume of nasopharyngeal carcinoma: Significance for recurrence and survival. Journal of the Chinese Medical Association: JCMA. 2008,71:461-466.
  7. Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: A meta-analysis of the phase III randomized trials. BMC Cancer. 2010;10:558. https://doi.org/10.1186/1471-2407-10-558
  8. Mayr NA, Riggs CE Jr, Saag KG, Wen BC, Pennington EC, Hussey DH. Mixed connective tissue disease and radiation toxicity. A case report. Cancer. 1997;79:612-618. https://doi.org/10.1002/(SICI)1097-0142(19970201)79:3<612::AID-CNCR26>3.0.CO;2-5
  9. Chen A, Obedian E, Haffty B. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J. 2001;7(6):480- 491.
  10. Teo P, Tai TH, Choy D. Nasophayngeal carcinoma with dermatomyositis. International Journal of Radiation oncology, Biology, Physics. 1989;16:471-474. https://doi.org/10.1016/0360-3016(89)90344-1
  11. Varga J, Haustein UF, Creech RH, Dwyer JP, Jimenez SA. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA: The Journal of the American Medical Association. 1991;265:3292-3295. https://doi.org/10.1001/jama.1991.03460240088033
  12. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Common Terminology Criteria for Adverse Events(CTCAE). J Am Acad Dermatol. 2012;67:1025-1039. https://doi.org/10.1016/j.jaad.2012.02.010
  13. Chen WC, Lai CH, Lee TF, Hung CH, Liu KC, Tsai MF, et al. Scintigraphic assessment of salivary function after intensitymodulated radiotherapy for head and neck cancer: Correlations with parotid dose and quality of life. Oral Oncology. 2013;49:42-48. https://doi.org/10.1016/j.oraloncology.2012.07.004
  14. Hadley T, Song C, Wells L, Lehnhardt J, Rogers MW, Anderson J, et al. Does hyperbaric oxygen therapy have the potential to improve salivary gland function in irradiated head and neck cancer patients? Medical Gas Research. 2013;3:15. https://doi.org/10.1186/2045-9912-3-15
  15. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology. 1993;11:1124-1131. https://doi.org/10.1200/JCO.1993.11.6.1124
  16. Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM, et al. Post-radiation severe xerostomia relieved by pilocarpine: A prospective French cooperative study. Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology. 2000;55:233-239. https://doi.org/10.1016/S0167-8140(99)00018-3
  17. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. The New England Journal of Medicine. 1993;329:390-395. https://doi.org/10.1056/NEJM199308053290603
  18. Jha N, Harris J, Seikaly H, Jacobs JR, McEwan AJ, Robbins KT, et al. A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in headand-neck cancer(RTOG 0244). International Journal of Radiation Oncology, Biology, Physics. 2012;84:437-442. https://doi.org/10.1016/j.ijrobp.2012.02.034
  19. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. Journal of the National Cancer In-- 19 - stitute. 2005;97:536-539. https://doi.org/10.1093/jnci/dji084
  20. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial.Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology. 2002;20:2038-2044. https://doi.org/10.1200/JCO.2002.08.149
  21. Abbasi F, Farhadi S, Esmaili M. Efficacy of Pilocarpine and Bromhexine in Improving Radiotherapy-induced Xerostomia. Journal of Dental Research, Dental Clinics, Dental Prospects. 2013;7:86-90.
  22. Kakoei S, Haghdoost AA, Rad M, Mohammadalizadeh S, Pourdamghan N, Nakhaei M, et al. Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Archives of Iranian Medicine. 2012;15:214-218.
  23. Kadar J, Petrovicz E. Adult-onset Still's disease. Best Practice & Research Clinical Rheumatology. 2004;18:663-676. https://doi.org/10.1016/j.berh.2004.05.004
  24. Neishi J, Tsukada Y, Maehara T, Ueki K, Maezawa A, Nojima Y. Adult Still's disease as a paraneoplastic manifestation of breast cancer. Scandinavian Journal of Rheumatology. 2000;29: 328-330. https://doi.org/10.1080/030097400447741
  25. Komano Y, Kubota T, Wakabayashi S, Ochi S, Nonomura Y, Hagiyama H, et al. A case of paraneoplastic syndrome mimicking adult-onset Still's disease. Modern rheumatology/the Japan Rheumatism Association. 2004;14:410-413. https://doi.org/10.3109/s10165-004-0333-2
  26. Wong P, Tam LS. Lymphoma in a patient with adult onset Still's disease refractory to immunosuppressants. Hong Kong Bull Rheum Dis. 2009;9:58-60.
  27. Sono H, Matsuo K, Miyazato H, Sakaguchi M, Matsuda M, Hamada K, et al. A case of adult-onset Still's disease complicated by non-Hodgkin's lymphoma. Lupus. 2000;9:468-470. https://doi.org/10.1191/096120300678828514
  28. Nakagawa Y, Furusyo N, Taniai H, Henzan H, Tsuchihashi T, Hayashi J. Chronic myelogenous leukemia that occurred two years after the diagnosis of adult Still's disease. Internal Medicine. 2005;44:994-997. https://doi.org/10.2169/internalmedicine.44.994
  29. Wu N, Li Q, Gu CX, Ahmed T, Yao XP. Paraneoplastic syndrome mimicking adult-onset Still's disease caused by advanced lung cancer: A case report. BMC Cancer. 2011;11:487. https://doi.org/10.1186/1471-2407-11-487
  30. Bosch-Barrera J, Montero A, Lopez-Picazo JM, Garcia-Foncillas J, Ferrer M, Yuste JR, et al. Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. Lung Cancer. 2009;64:124-126. https://doi.org/10.1016/j.lungcan.2008.09.013